US SEC Filing Intelligence

New Federal Contractors — August 01, 2026

This digest covers $975.6 million in new federal obligations from August 2026, with 3 of 4 contracts defense-related but a dominant civilian agency (HHS) accounting for 71% of total value. The highest-conviction signal is a $695.7 million BARDA contract to Regeneron Pharmaceuticals, a bullish, competitive win with low pricing risk that provides long-term revenue visibility through 2027. However, the aggregate signal strength is low (4.0/10) due to three neutral, historical contracts from AT&T and Lockheed Martin that offer no forward revenue contribution. Key risks include the lack of clarity on Regeneron’s specific deliverables and the concentration of value in a single, long-duration contract.

Significant Contract Modifications ($10M+) — August 01, 2026

The August 2026 contract stream totals $975.6 million, with 3 of 4 awards defense-related, though the dominant award is a $695.7 million civilian biotech contract to Regeneron Pharmaceuticals from HHS/BARDA, representing 71% of total value and the only bullish signal. The defense contracts are legacy awards to AT&T and Lockheed Martin, all completed, offering no forward revenue. The highest-conviction signal is Regeneron's cost-plus-fixed-fee contract, which provides low-risk, long-term revenue through 2027, but execution and funding pace remain key watch items. The stream is skewed by one mega-award, with limited actionable defense signals, and investors should focus on Regeneron's BARDA relationship and potential follow-ons.

Contract Deobligations Alert — August 01, 2026

This digest covers $975.6 million in total obligations across four contracts, with three of four being defense-related (NASA and State Department) and one large civilian award from HHS/BARDA. The dominant signal is a $695.7 million cost-plus-fixed-fee contract to Regeneron Pharmaceuticals for biodefense R&D, representing the highest-conviction bullish signal due to its competitive win, low pricing risk, and long-term revenue visibility through 2027. However, the remaining three contracts (AT&T, two Lockheed Martin awards) are all completed or historical, offering no forward revenue contribution and diluting the aggregate signal strength to a neutral 4.0/10. Key risk: the Regeneron contract's vague program description limits visibility into specific deliverables and execution milestones, while the three completed contracts provide no ongoing investment catalyst.

Contract Option Exercises — August 01, 2026

This digest covers $975.6 million in contract option exercises from August 1, 2026, with 3 of 4 awards defense-related but only one—Regeneron Pharmaceuticals' $695.7 million BARDA contract—carrying material forward-looking investment weight. The Regeneron award dominates the aggregate (71% of total value) and is the sole bullish signal, reflecting stable, cost-plus-funded biodefense R&D through 2027. The other three contracts are historical or completed awards (AT&T State Department telecom, two Lockheed Martin NASA R&D contracts) offering no current revenue contribution. Key risk: the Regeneron contract's vague program description limits visibility into specific deliverables and milestone timing, creating execution uncertainty despite low pricing risk.

Federal Professional Services Contracts — August 01, 2026

This digest covers a single $17.3M obligation from a $39.95M NASA cost-plus-fixed-fee contract awarded to Lockheed Martin in 2014 for advanced technology R&D. The contract is entirely civilian (NASA) and ended in August 2020, making it a historical data point with no current revenue contribution. The neutral signal (strength 3/10, materiality 2/10) reflects the low risk for Lockheed due to the cost-plus structure and sole-source award, but the lack of current relevance limits actionable insight. The key risk is that any follow-on recompetition could introduce competitive pressure on Lockheed’s incumbency at NASA Ames Research Center.

1 total filings

All HHS Contracts — August 01, 2026

The sole HHS contract in this period is a $695.7 million cost-plus-fixed-fee biotechnology R&D award from BARDA to Regeneron Pharmaceuticals, representing a significant, long-duration (10-year) revenue stream for the company. While classified as defense-related (1/1), this is a civilian biodefense and pandemic preparedness investment, not a traditional defense procurement. The highest-conviction signal is the cost-plus pricing structure, which minimizes profit volatility and ensures cost recovery for Regeneron, though the vague contract description and long performance period introduce execution uncertainty. Key watch items include the pace of future outlays ($238.8M already spent) and any contract modifications that could expand or adjust the scope. Overall, this contract underscores HHS's sustained commitment to advanced medical countermeasures, a stable-to-growing sector with strategic importance.

1 total filings

Mega Contracts Monitor ($100M+) — August 01, 2026

The two contracts analyzed total $956.9 million in obligations, with one defense-related award (AT&T to State Department) and one civilian award (Regeneron to HHS). The dominant theme is civilian biodefense R&D, driven by Regeneron's $695.7 million cost-plus-fixed-fee contract from BARDA, which provides stable, long-term revenue visibility through 2027. The highest-conviction signal is bullish for Regeneron, given the low pricing risk and competitive win, though the vague program description introduces execution uncertainty. The AT&T contract is a completed award with no ongoing revenue, offering limited forward-looking insight. Key risk: the Regeneron contract's 10-year duration and lack of specific deliverables could lead to underperformance or scope changes.

2 total filings

High-Value Federal Grants ($5M+) — August 01, 2026

This digest covers $974.2 million in government obligations from August 2016, with a 2/3 defense-related tilt but dominated by a single civilian award. The dominant theme is a massive $695.7 million cost-plus-fixed-fee contract from HHS/BARDA to Regeneron Pharmaceuticals for biotechnology R&D, representing the highest-conviction signal due to its size, low-risk pricing structure, and long 10-year performance period through 2027. Two smaller, historical contracts from AT&T ($261.1M, completed) and Lockheed Martin ($17.3M, completed) offer no current revenue contribution, making Regeneron the sole actionable investment signal. Key risk is the vague contract description ('IGF::OT::IGF'), which limits visibility into specific program deliverables and execution milestones.

3 total filings

General Federal Contracts — August 01, 2026

This digest covers $974.2 million in federal obligations across three contracts, with 2 of 3 being defense-related (BARDA/HHS and NASA) and one civilian (State Department). The dominant signal is Regeneron Pharmaceuticals' $695.7 million cost-plus-fixed-fee contract from BARDA, which represents a high-conviction, low-risk revenue stream for biodefense R&D through 2027. However, the two other contracts—AT&T's $261.1 million State Department telecom award and Lockheed Martin's $17.3 million NASA R&D contract—are both completed (ended in 2020-2021), offering no current revenue contribution and reducing the overall actionable insight. Key risk: the AT&T and Lockheed contracts are historical, limiting forward-looking investment relevance.

3 total filings

All NASA Contracts — August 01, 2026

Over the period of August 1, 2026, NASA awarded Lockheed Martin Corporation two cost-plus-fixed-fee contracts totaling $18.76 million, both defense-related and neutral in signal. The larger $17.32 million award (historical, ended 2020) and the smaller $1.44 million delivery order (completed December 2023) represent low-risk, stable-margin work but offer no current revenue contribution or forward visibility. The dominant theme is Lockheed Martin's entrenched sole-source position for NASA R&D services, though the contracts are too small to materially impact its $60B+ revenue base. Key risks include the lack of follow-on awards or recompetition triggers, which could signal competitive erosion or program phase-out. Investors should monitor for new NASA Ames task orders under PISCES or similar programs to gauge Lockheed's incumbency durability.

2 total filings

Biotech Small-Cap Approvals — July 31, 2026

This digest covers 22 FDA approvals from July 27-29, 2026, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion) per the provided data, with a mix of 4 bullish and 18 neutral signals. The dominant theme is a massive wave of biosimilar approvals for SUGAMMADEX SODIUM, with 12 separate sponsors (HIKMA, STERISCIENCE, TEVA, FRESENIUS KABI, MANKIND PHARMA, ZENARA, SANDOZ, SUN PHARM, MYLAN, LUPIN, GLAND, MSN) all receiving approval on the same day, signaling imminent and severe revenue erosion for the originator (Merck's BRIDION). The highest-conviction bullish signals include label expansions for CLONIDINE HYDROCHLORIDE (CMP DEV LLC), Ruxolitinib (APOTEX), and an unknown drug from VIATRIS SPECIALTY, though commercial details are undisclosed. Key risks include the competitive pricing pressure from the SUGAMMADEX SODIUM biosimilar cluster and the lack of NME approvals, which limits high-value catalyst opportunities for the period.

22 total filings

New Drug Approvals (Original) — July 31, 2026

This digest covers 22 FDA approvals from July 27-29, 2026, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion). The dominant theme is a massive wave of generic/biosimilar competition for SUGAMMADEX SODIUM, with 11 separate approvals granted to sponsors including HIKMA, TEVA, SANDOZ, SUN PHARM, MYLAN, LUPIN, and others, signaling an imminent and severe revenue erosion event for the originator (Merck's BRIDION). The highest-conviction bullish signals are four label expansions for CLONIDINE HYDROCHLORIDE (CMP DEV LLC), Ruxolitinib (APOTEX), and two undisclosed drugs from FRESENIUS KABI USA and VIATRIS SPECIALTY, though their commercial materiality is low. The key risk is the complete absence of NME approvals, indicating a quiet period for innovative drug catalysts, while the SUGAMMADEX SODIUM cluster is the single most impactful event for generic manufacturers and a bearish signal for the originator.

22 total filings

DHS Homeland Security Contracts — July 31, 2026

This digest covers a single, large civilian contract from the Department of Homeland Security (DHS) to Serco Services Inc. worth $321.3 million, representing the entire $321.3 million aggregate obligation for the period. The contract, awarded in 2009 and completed in 2016, is a historical artifact with zero current outlays, providing no actionable forward-looking revenue signal for Serco. The neutral signal strength (4/10) and low materiality (2/10) reflect the contract's expired status and mature, low-margin administrative services nature. The key risk is the lack of current DHS contract data for Serco, creating a visibility gap on its civilian backlog, while the key watch item is any potential follow-on or recompete for USCIS National Benefits Center support.

1 total filings

New Federal Contractors — July 31, 2026

This digest covers four civilian agency contracts totaling $1.07 billion in obligations, with zero defense-related awards. The dominant theme is stable, low-margin federal services across environmental remediation (DOE), administrative support (DHS), engineering R&D (NASA), and clinical research (NIH). The highest-conviction signal is a $173.3 million NIH contract to Technical Resources International, Inc., a small, woman-owned business, offering predictable long-term revenue through 2026. However, three of the four contracts are either completed or near-expiration, limiting near-term revenue visibility. Key risk: the $321.3 million Serco Services Inc. DHS contract is expired with $0 outlayed, signaling no current contribution from that award.

Significant Contract Modifications ($10M+) — July 31, 2026

This digest covers $1.07 billion in federal contract modifications, all from civilian agencies (0% defense), signaling a concentrated investment opportunity in environmental remediation and health R&D services. The dominant theme is long-duration, cost-plus federal work at the Department of Energy (Hanford cleanup) and the National Institutes of Health (clinical research), where pricing risk is low but revenue visibility varies. The highest-conviction signal is Technical Resources International, Inc.'s $173.3 million NIH contract, which provides a stable, nearly decade-long revenue stream through 2026. A key risk is the short duration of Central Plateau Cleanup Company's $371.6 million DOE award, which limits near-term revenue recognition and exposes the contractor to option-exercise uncertainty.

Contract Deobligations Alert — July 31, 2026

This digest covers $1.07 billion in federal contract obligations from July 31, 2026, with zero defense-related awards, underscoring a purely civilian procurement theme. The dominant sector is environmental remediation, led by a $371.6 million DOE Hanford award to Central Plateau Cleanup Company (PAE-Parsons), though its short duration and low outlay limit near-term impact. The highest-conviction signal is a $173.3 million NIH clinical research contract to Technical Resources International, offering a stable, long-term revenue stream through 2026. Key risks include the expiration of a $321.3 million Serco DHS contract with no current outlay and the completion of a $202.6 million NASA engineering award to Millennium Engineering, both reducing current revenue visibility for those firms.

Contract Option Exercises — July 31, 2026

This digest covers $1.07 billion in contract option exercises from July 31, 2026, all from civilian agencies (0% defense-related), with an average signal strength of 5.0/10. The dominant theme is federal environmental remediation and health R&D services, led by a $371.6 million DOE Hanford cleanup award to Central Plateau Cleanup Company (PAE-Parsons) and a $173.3 million NIH clinical research contract to Technical Resources International. The highest-conviction signal is the bullish, long-duration NIH contract to Technical Resources International, which provides stable, low-risk revenue through 2026. A key risk is the short 8-month performance period and low outlay ($125.4M) on the largest contract, limiting near-term revenue visibility for PAE-Parsons.